Key Takeaway
The GLP-1 telehealth market has over 105 active providers in 2026. We expect only 30-40 viable operators by 2028, a 60-70% attrition rate. Three forces drive the shakeout: the FDA compounding crackdown, Novo Nordisks direct deals with major platforms, and a 340% rise in customer acquisition costs.
Last reviewed: 2026-04-16
The GLP-1 gold rush is ending. What started as an open market for compounded semaglutide in 2023 has turned into a regulatory, pharma, and capital squeeze that most small operators cant survive. Our team tracks this market weekly. Here is the honest assessment of whos safe, whos at risk, and whos already dead.
If youre picking a provider right now, youll want to know which ones will still exist in 24 months. For the full dataset behind these predictions, read the State of GLP-1 telehealth 2026 report.
Why is the GLP-1 telehealth market consolidating?
Three forces are squeezing the market at once: regulatory pressure on compounded products, pharma direct-to-consumer deals, and paid acquisition costs that most operators cant afford. The result is a shakeout that started in late 2025 and will run through 2027.
The FDA has issued 85+ warning letters to compounding pharmacies and telehealth operators since the shortage designation ended. That single regulatory shift erased the compounded cost advantage for any operator selling semaglutide below $200 a month. Without ultra-cheap compounded supply, the business model breaks.
Customer acquisition costs tell the second half of the story. Per Measured Analytics, paid search CPCs for GLP-1 keywords rose 340% between 2023 and 2026. A $600 CAC on a $299/month subscription doesnt pencil out when churn sits at 35-50% annually, which it does across most operators weve analyzed.
Which providers are almost certain to survive?
Seven operators sit in the safe tier. They have scale, capital, and in most cases a direct supply deal with Novo Nordisk or Eli Lilly. If youre choosing a provider today and want the lowest probability of disruption, start here.
Hims & Hers reported $2.35B in revenue for 2025 and is public. Its Novo Nordisk direct partnership gives it branded Wegovy at a meaningful discount. Ro raised at a $7B valuation and also signed a direct Novo deal. Noom carries a $3.7B valuation and has pivoted aggressively into GLP-1 prescribing alongside its behavioral program. WW Clinic, Amazons One Medical, LillyDirect, and NovoCare round out the tier. The common thread is distribution, capital, or pharma alignment.
You can see full profiles and pricing for these operators in the FormBlends provider directory.
Which providers are at high risk of shutting down?
The at-risk tier is larger and messier. It includes most of the 60+ compounding-focused operators that launched between 2023 and 2025. Many are underfunded, dependent on compounded supply, and burning cash on paid search.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →Providers already under FTC or FDA action are in the worst position. NextMed shut down in 2025 after regulatory pressure and BBB complaints. Others graded F by the Better Business Bureau, or operating without clear medical oversight, face a similar path. Specific warning signs we track: no licensed medical director named on the site, no clear adverse event reporting pathway, monthly prices under $150 for compounded products, and refund complaints outpacing resolution.
For a breakdown of how to vet operators you cant yet rule out, see our guide to vetting a GLP-1 provider.
Survival predictions by tier
Heres the forecast across four tiers. Numbers reflect our 2026 tracking set of 105+ operators and our base-case 2028 outlook.
| Tier | 2028 survival probability | Example operators | Key driver |
|---|---|---|---|
| Safe | 90%+ | Hims, Ro, Noom, WW Clinic, Amazon/One Medical, LillyDirect, NovoCare | Scale, public capital, pharma deals |
| Likely | 60-80% | Found, LifeMD, Teladoc, Omada, FormBlends | Differentiated product or enterprise channel |
| At risk | 20-40% | Most compounding-only operators without quality signals | FDA pressure, CAC squeeze, no pharma supply |
| Wont survive | Under 10% | Operators already under FTC/FDA action, F-rated BBB | Regulatory enforcement, insolvency |
What acquisitions have already happened in 2025-2026?
The consolidation is already visible in deal flow. Four recent transactions set the template for what the next 18 months look like. Expect more roll-ups, fewer standalone raises, and pharma distribution deals replacing venture rounds.
Remedy Meds acquired Thirty Madison for $500M in an all-stock deal, combining two large direct-to-consumer platforms. Hims acquired Zava to push into EU markets. Amazon closed its $3.9B purchase of One Medical, giving it a primary-care delivery backbone for GLP-1 prescribing. Accolade acquired PlushCare for $450M, folding a telehealth prescriber into an employer-benefits platform.
The pattern is clear. Scaled buyers are picking up distribution, licensed provider networks, and customer books. Smaller operators without either are running out of exit paths and fresh capital. If you want to track these deals in real time, the 2026 report updates monthly.
How does pharma direct-to-consumer change the math?
Novo Nordisk and Eli Lilly have redrawn the market by going direct. Novos deals with Hims, Ro, LifeMD, GoodRx, and Walgreens create a two-tier market. Tier one gets branded Wegovy or Ozempic at a preferred price. Tier two doesnt, and has to sell compounded or cash-pay branded products at a disadvantage.
LillyDirect and NovoCare, the pharma-operated channels, add another layer. Patients can buy Zepbound or Wegovy straight from the manufacturer with simpler logistics than many telehealth brands offer. This takes the most price-sensitive branded-product buyers out of the telehealth funnel entirely.
The operators caught in the middle, compounding-only shops without pharma deals, lose on both sides. They cant match the pharma direct price on branded product, and they cant hold compounded pricing under FDA enforcement. Thats why our at-risk tier is so large.
What does this mean for patients choosing a provider today?
Pick an operator that will still exist in 2028. Thats the most practical guidance we can give. A mid-course provider shutdown isnt an academic risk. It means lost medical records, interrupted supply, and a new evaluation to find a replacement, all while youre mid-protocol.
Practical screen: does the provider have named medical leadership, a BBB rating of B or better, a clear pathway to branded Wegovy or Zepbound if you want or need to switch off compounded, and pricing that isnt dependent on sub-$200 compounded semaglutide? If yes to all four, youre likely in a tier-one or tier-two operator.
FormBlends sits in the likely-survive tier. We prioritize licensed medical oversight, transparent pricing, and a compliance posture built for the post-shortage regulatory environment. If youre ready to start, you can begin your consultation here or review FormBlends products and pricing.
For a closer look at how to compare specific operators, see our Hims vs Ro vs FormBlends comparison.
Frequently asked questions
How many GLP-1 telehealth providers exist in 2026?
Our tracking set includes 105+ active operators in the US as of Q1 2026. That count excludes compounding pharmacies that dont also run a consumer-facing telehealth brand and excludes employer-only programs.
How many will survive to 2028?
Our base case is 30-40 viable operators by end of 2028. That implies 60-70% attrition across the current field. The range reflects uncertainty about how fast FDA enforcement moves and how many pharma direct deals materialize.
Is my current provider going to shut down?
You can self-check quickly. Look for named medical leadership, a B-or-better BBB rating, a pathway to branded products, and pricing not built around cheap compounded supply. If any are missing, your provider is in the at-risk tier.
What happens to my prescription if my provider closes?
In most cases youll need a new evaluation with a different licensed provider. Some operators offer medical-record export, but many dont. Ask before you sign up. You can read more in our guide to switching providers.
Are compounded semaglutide providers all doomed?
No, but the ones without differentiation are. Compounders with strong quality systems, licensed medical oversight, and niche positioning can survive. The ones competing only on price below $200/month cant.
Why will pharma direct channels keep growing?
LillyDirect and NovoCare cut out the middleman for patients who want branded product at the lowest legitimate price. Those channels scale with near-zero marginal distribution cost for the manufacturer, which telehealth operators cant match.
How does FormBlends expect to survive?
We focus on medical rigor, compliant supply, and a patient experience built for long-term protocols, not one-shot sales. Our economics dont depend on sub-$200 compounded pricing, and were investing in the care model rather than paid search arbitrage.
Medical disclaimer: This article is for educational purposes only and is not medical advice. Always consult your healthcare provider before starting any medication. Individual results vary. FormBlends is a licensed telehealth platform; nothing here replaces a personal clinical evaluation.